Effects of Carvedilol combined with Somatostatin in the treatment of esophageal and gastric varices bleeding in patients with liver cirrhosis
Objective:To observe effects of Carvedilol combined with Somatostatin in the treatment of esophageal and gastric varices bleeding in patients with liver cirrhosis.Methods:The clinical data of 75 liver cirrhosis patients with esophageal and gastric varices bleeding admitted to this hospital from January 2019 to February 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group(n=37)and observation group(n=38).Both groups were given routine treatment.On this basis,the control group was treated with Somatostatin,while the observation group was treated with Carvedilol on the basis of that of the control group.The levels of clinical indexes(hemostasis time,hospitalization time and blood transfusion volume),the portal vein indexes(portal vein pressure,portal vein blood flow velocity and portal vein blood flow volume)levels before and after the treatment,the incidence of adverse reactions,and the incidence of rebleeding were compared between the two groups.Results:The hemostasis time and the hospitalization time of the observation group were shorter than those of the control group,the blood transfusion volume was less than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the portal vein pressure,the portal vein blood flow velocity and the portal vein blood flow in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The incidence of rebleeding in the observation group was 7.89% (3/38),which was lower than 27.03% (10/37)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Carvedilol combined with Somatostatin in the treatment of the liver cirrhosis patients with esophagogastric variceal bleeding can improve the level of clinical indexes and reduce the levels of portal vein indexes and the incidence of rebleeding.Moreover,it is superior to single Somatostatin treatment.
SomatostatinCarvedilolLiver cirrhosisEsophageal and gastric varices bleedingPortal veinAdverse reactionRebleeding
万方数据
维普
